Abstract
Eckermann and Pekarsky have written a thought-provoking paper that challenges a number of existing concepts, including methods for determining the cost-effectiveness threshold for appraising new health technologies for potential adoption into a public healthcare system.
Previously proposed approaches to defining the threshold have included the estimation of the societal monetary value of a QALY to inform the net monetary benefits of new technologies, where the technology is funded if the net benefits are positive. Alternative approaches aim to represent opportunity cost, either by focusing on the QALYs forgone from the displacement of services to generate resources to fund new technologies, or as a retrospective estimate of expected QALY gains from budget expansion or contraction at the margin
Previously proposed approaches to defining the threshold have included the estimation of the societal monetary value of a QALY to inform the net monetary benefits of new technologies, where the technology is funded if the net benefits are positive. Alternative approaches aim to represent opportunity cost, either by focusing on the QALYs forgone from the displacement of services to generate resources to fund new technologies, or as a retrospective estimate of expected QALY gains from budget expansion or contraction at the margin
| Original language | English |
|---|---|
| Pages (from-to) | 315-318 |
| Number of pages | 4 |
| Journal | Pharmacoeconomics |
| Volume | 32 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2014 |
| Externally published | Yes |
Keywords
- Cost-effectiveness
- QALY
- monetary benefits